Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Hemophilia Treatment Market to 2027 – Global Analysis and Forecasts by Product; Disease; Treatment Type; Therapy; End User,…
The U.S. Food and Drug Administration (FDA) has granted 510(k) marketing clearance to Shire’s myPKFiT for ADVATE, a free web-based…
Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene.